Welcome

Photo of STA Office

Specialised Therapeutics Australia (STA) is a bio-pharmaceutical company dedicated to working with leading international pharmaceutical and diagnostic companies to provide patient access to innovative healthcare solutions.

STA Commercialises, with the Highest Professional and Ethical Standards, Innovative Therapies and Technologies that Uniquely Fulfil the Unmet Medical Needs of our Community.

March, 2016: Specialized Therapeutics Grants Sublicense for Anti-Emetic Products to Mundipharma for Australia and New Zealand

Specialized Therapeutics Pty Ltd and Mundipharma Pty Limited today announce a sublicense agreement enabling Mundipharma to assume all commercialisation responsibilities for the anti-emetic products ALOXI® (palonosetron hydrochloride) and AKYNZEO® (netupitant/palonesetron).

Read More

October, 2015: STA Supply ICLUSIG™ (ponatinib) Direct to Pharmacies Nationwide

Following the PBS listing of ICLUSIG on November 1 2015 STA will be supplying pharmacies direct for orders of ICLUSIG placed with our customer service department or via our online ordering facility.

Read More

March, 2014: Rare Cancers Australia - A focus on less common cancers

Two articles / reports on less common cancers from Rare Cancers Australia.

Read More

October, 2015: ICLUSIG PBS Listed November 1 2015

Specialised Therapeutics Australia (STA) is delighted to announce that ICLUSIG has received a confirmed listing date of 1 November 2015.

Read More

Jan, 2014: Updated Pancreatic Cancer Data Presented At International Cancer Conference

A leading breast cancer drug, ABRAXANE® (nanoparticle albumin-bound paclitaxel), has been shown to extend overall survival (OS) for patients with metastatic pancreatic cancer when used in combination with current standard of care, gemcitabine, with some patients surviving longer than three years.

Read More

Jun 2016: Specialised Therapeutics Strikes Deal With World Courier Australia To Manage Logistics For Specialty Pharma Products

World Courier Australia selected to manage all delivery, storage operations for STA’s growing portfolio of specialist healthcare products

Read More

Mar 2016: Novel Multiple Myeloma Drug Aplidin® Shows Positive Results In Pivotal Phase 3 Study

Phase 3 trial of APLIDIN/dexamethasone combination showed “statistically significant” 35% reduction in risk of disease progression or death compared to dexamethasone alone

Read More

Feb 2016: Specialised Therapeutics Asia To Distribute Novel Multiple Myeloma Drug APLIDIN® In South East Asia, Australia And New Zealand

International biopharmaceutical company Specialised Therapeutics Asia (ST Asia) will supply and distribute a novel oncology drug candidate throughout South East Asia, following an exclusive licensing deal with European pharmaceutical company PharmaMar.

Read More

Sep 2015: TAILORx trial finds 99 percent of women with low Oncotype DX® Recurrence Score® results are free of breast cancer recurrence after five years of hormone therapy alone

The presentation of the first results from the Trial Assigning IndividuaLised Options for Treatment (Rx), or TAILORx, a large, prospectively conducted trial, designed and conducted by the ECOG-ACRIN Cancer Research Group under the sponsorship of the U.S. National Cancer Institute (NCI).

Read More

Sep 2015: Specialised Therapeutics’ Breakthrough Brain Tumour Visualisation Drug GLIOLAN® Approved For Use in New Zealand

A novel drug which helps neurosurgeons to better visualise and remove malignant brain tumours has been approved for marketing and distribution in New Zealand by Medsafe.

Read More